Skip to Content

Generic Clolar Availability

Clolar is a brand name of clofarabine, approved by the FDA in the following formulation(s):

CLOLAR (clofarabine - solution;intravenous)

  • Manufacturer: GENZYME
    Approval date: December 28, 2004
    Strength(s): 20MG/20ML (1MG/ML) [RLD] [AP]

Has a generic version of Clolar been approved?

A generic version of Clolar has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Clolar and have been approved by the FDA:

clofarabine solution;intravenous

  • Manufacturer: ABON PHARMS LLC
    Approval date: May 9, 2017
    Strength(s): 20MG/20ML (1MG/ML) [AP]
  • Manufacturer: AMNEAL PHARMS CO
    Approval date: November 6, 2017
    Strength(s): 20MG/20ML (1MG/ML) [AP]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: November 6, 2017
    Strength(s): 20MG/20ML (1MG/ML) [AP]
  • Manufacturer: GLAND PHARMA LTD
    Approval date: October 31, 2018
    Strength(s): 20MG/20ML (1MG/ML) [AP]
  • Manufacturer: INGENUS PHARMS LLC
    Approval date: September 14, 2018
    Strength(s): 20MG/20ML (1MG/ML) [AP]
  • Manufacturer: MSN LABS PVT LTD
    Approval date: December 6, 2017
    Strength(s): 20MG/20ML (1MG/ML) [AP]
  • Manufacturer: MYLAN LABS LTD
    Approval date: November 6, 2017
    Strength(s): 20MG/20ML (1MG/ML) [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Clolar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 2-halo-2'-fluoro ARA adenosines as antinoplastic agents
    Patent 5,661,136
    Issued: August 26, 1997
    Inventor(s): Montgomery; John A. & Secrist, III; John A.
    Assignee(s): Southern Research Institute

    The present invention is directed to certain 2'-fluoro, 2-substituted purine nucleosides which are toxic to cancerous cell lines.

    Patent expiration dates:

    • January 14, 2018
    • July 14, 2018
      Pediatric exclusivity

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.